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Abstract 
 
A simple and rapid ultra-high performance liquid chromatography-mass 
spectrometry/mass spectrometry (UPLC-MS/MS) method has been developed for 
measuring intracellular concentrations of the anticancer agent 7-ethyl-10-
hydroxycamptothecin (SN-38) in tumour cells using camptothecin (CPT) as internal 
standard. SN-38 extraction was carried out using acidified acetonitrile. SN-38 and CPT 
were separated on a PFP column using gradient elution with acidified water and 
acetonitrile. SN-38 and CPT were quantified using a triple quadrupole mass spectrometry 
system. Least square regression calibration lines were obtained with average correlation 
coefficients of R
2
 = 0.9993  0.0016. The lower limit of detection (LOD) and lower limit 
of quantification (LOQ) for SN-38 were 0.1 and 0.3 ng/ml, respectively. CPT recovery 
was 98.5  13% and SN-38 recoveries at low quality control (LQC, 5ng/ml) and high 
quality control (HQC, 500ng/ml) were 89  6% and 95  8%, respectively. The intra- and 
inter-day imprecision for LQC was 6.0 and 9.2%, and for HQC was 4.7 and 7.1%., 
respectively. The method was compared to a validated high performance liquid 
chromatography-fluorescent method. In addition, the method has been successfully 
applied to determine the intracellular accumulation of SN-38 investigating the transport 
through ABCB1 (P-gp) and ABCG2 (BCRP) efflux pumps in colorectal cancer cell lines. 
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1. Introduction 
Irinotecan is mainly used in the treatment of colorectal cancer either alone or in 
combination with other drugs. SN-38 is the active metabolite of irinotecan (Figure 1). 
Irinotecan is converted to 7-ethyl-10-hydroxycamptothecin (SN-38) by human 
carboxylesterase (hCE) [1]. Irinotecan belongs to a class of anti-cancer drugs known as 
topoisomerase I poisons. Topoisomerase I enzymes allow DNA to relax by causing single 
stranded breaks, unwinding of DNA for replication to occur, and then re-annealing of the 
DNA double helix. If single stranded breaks remain due to the binding of SN-38, it 
ultimately leads to apoptosis of the affected cell. 
SN-38 can undergo glucuronic acid conjugation and thus detoxification to form SN-38 
glucoronide inside the body. The extent to which this occurs can greatly alter the side 
effects of irinotecan therapy such as diarrhoea [2]. Polymorphisms of UDP-
glucuronosyltransferase (UGT) 1A1 enzyme can be associated with accumulation of SN-
38 with increased risk of toxicity [3]. Therefore, plasma concentrations of SN-38 could 
serve as a useful marker predicting toxicity when irinotecan is given to cancer patients. In 
addition, intracellular concentrations of SN-38 are also thought to vary due to efflux of 
SN-38 via drug efflux pumps such as breast cancer–related protein (ABCG2). This efflux 
system may vary between tumour types and confers resistance to the drug [4]. So, 
measuring intracellular SN-38 could serve as an additional marker for drug 
activity/toxicity in patients. 
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Previous HPLC quantitative methods described for SN-38 were mainly for plasma or 
liposomes as opposed to intracellular measurements [5-14]. Some of the plasma methods 
were adapted to quantify intracellular SN-38 but without full validation of the optimised 
methods [15,16]. Other groups [17,18] have successfully developed specific methods for 
intracellular measurements. However, these methods were aimed primarily at separating 
the lactone and hydroxy forms of SN-38 and involved complex chromatography leading 
to long run times. In addition, SN-38 peak tailing was notable despite the use of ion 
pairing. Therefore, we have developed and validated this novel ultra-high performance 
liquid chromatography-mass spectrometry/mass spectrometry (UPLC-MS/MS) method 
specifically for the determination of intracellular total SN-38 (hydoxy + lactone); with the 
aims of shortening the run time and improving SN-38 peak resolution. The method was 
developed using a pentafluoryl phenyl (PFP) UPLC column which allowed fast analysis 
and good peak shape without the need for ion-pairing agents. Moreover, the method 
applicability was tested in a panel of colorectal cancer cell lines and the results were 
compared to a validated high performance liquid chromatography-fluorescent (HPLC-
Flu) method which have been used in a number of previous studies [4,19,20]. 
 
2. Material and methods 
 
2.1 Materials 
 
SN-38, CPT-(s)-(+)-Camptothecin, Ciclosporin A, Fumitremorgin C, Sodium dodecyl 
sulphate (SDS) GC grade, Hanks balanced salt solution and Dulbecco’s modified Eagles 
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Medium were all obtained from Sigma Aldrich, (Dorset, UK). AnalaR grade HCl and 
NaH2PO4 were obtained from VWR, (West Sussex, UK). Trypsin was purchased from 
Invitrogen, (Paisley, UK). LC-MS grade formic acid (FA), water, methanol and 
acetonitrile (ACN) were all obtained from Fisher Scientific, (Loughborough, UK) and 
SN-38 from Pfizer, (Cambridge, UK). HT29, and SW620 cell lines were obtained from 
the American Type Culture Collection (Teddington, Middlesex, UK). HCT116 was 
obtained from the European Collection of Cell Cultures (Wiltshire, UK) 
 
2.2 Instrumentation, chromatographic and mass spectrometry conditions 
 
SN-38 and CPT were separated on an Accela UPLC system, Thermo Scientific, (Hemel 
Hempstead, UK) equipped with Kinetex 1.7 µm PFP, LC Column 100 × 2.1 mm obtained 
from Phenomenex, (Macclesfield, Cheshire, UK). Gradient elution was employed using a 
mobile phase of 0.1% FA in water (buffer A) and 0.1% FA in ACN (buffer B) as follows: 
Buffer A = 70% at 0 min, from 70 to 10% over 2 minutes, held at 10% for 1 minute, from 
10 to 70% over 0.1 minutes, ending with 70% for 3 minutes, all at a flow rate of 250 
µl/min.  
Triple-stage-quadrupole mass spectrometry (TSQ) Vantage system, Thermo Scientific, 
(Hemel Hempstead, UK) equipped with an electrospray ion source was used for mass 
detection. Samples were analyzed in the Multiple Reaction Monitoring (MRM), positive 
mode at a spray voltage of 3500 V. Nitrogen was used as sheath and auxiliary gases at a 
flow rate of 30 and 10 arbitrary units, respectively. Argon was used as collision gas with 
pressure of 1.5 mTorr. The optimum transitional daughter ion mass and collision energy 
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for SN-38 was: m/z 393.1  349.4 (collision energy 25V) and for CPT: m/z 349.1  
305.4 (collision energy 23V). Data acquisition and chromatography analysis were carried 
out using Xcalibur software version 2.2 from Thermo Scientific, UK. 
 
The HPLC-Flu system consisted of Perkin Elmer series 200 HPLC system (Perkin Elmer, 
Cambridge, UK) equipped with Luna ODS, C18(2), 3 µm, 150 × 4.6mm ID, from 
Phenomenex (Macclesfield, Cheshire, UK), fitted with a C18 security guard cartridge 
also from Phenomenex (Macclesfield, Cheshire, UK). Analytes were eluted using an 
isocratic mobile phase consisting of 50 mM NaH2PO4 buffer (pH 3.1) containing 10 mM 
SDS 65%: ACN 35%. At a flow rate of 1 ml/min. Analytes were detected using Perkin 
Elmer series 200 HPLC fluorescence detector equipped with a xenon lamp operating at 
wavelengths of 380 and 540 nm for excitation and emission, respectively. Data 
acquisition and chromatography analysis was carried out using Turbochrom software 
version 6.2.1 from Perkin Elmer (Cambridge, UK). 
 
2.3 Cell extraction procedure 
 
Cell samples were pelleted by centrifugation at 600 g, each containing 6 million cells. 
After removal of supernatant, 200µl of 50% ACN containing 0.5% FA and 1 µg/ml CPT 
was added to each sample, vortexed for 60 seconds and placed on ice for 30 min to allow 
protein precipitation to occur. Samples were then spun at 10,000 g, 4
 o
C, for 10 min to 
pellet the cell precipitate. 150µl supernatant was then transferred into LC-MS vials and 
10 µl injected directly into the UPLC-MS system. 
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2.4 Preparation of standards and controls 
 
SN-38 and CPT stock solutions were prepared at 1 mg/ml by dissolving in DMSO and 
chloroform/methanol (4:1 vol:vol), respectively.  
 
Working standards of SN-38 at the following concentrations 0.1, 0.3, 1, 3, 10, 30, 100, 
300 and 1000 ng/ml were prepared by diluting SN-38 stock in pooled drug free cell 
pellets. Quality control samples (QC) of 5, 50 and 500 ng/ml were prepared by dilution of 
SN-38 stock in pooled drug free cell pellets. 
 
Linearity of the assay was determined by injecting the working standards into the UPLC 
system. The peak area of each analyte concentration was divided by the peak area of CPT 
internal standard. The resultant ratio was then plotted against the concentration using a 
weighted (1/x
2
) quadratic least square regression model, where x is the concentration and 
y is the peak area ratio. 
 
2.5 Sensitivity 
 
The lower limited of detection (LOD) was determined as the concentration of extracted 
SN-38 that had a peak area ratio 3 times higher than the baseline noise. The lower limit of 
quantitation (LOQ) was determined as the lowest conc. of extracted SN-38 with 
imprecision < 10% and inaccuracy <15%. 
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2.6 Imprecision and inaccuracy 
 
Interday imprecision was determined by extraction and analysis of three QC samples of 
known concentration 5 ng/ml (Low Quality Control; LQC), 50 (Middle Quality Control; 
MQC) and 500 ng/ml (High Quality Control; HQC) over 6 different days. 
 
Intraday imprecision was determined by extraction and analysis of 6 replicates of each of 
the two QC samples within the same run. 
 
Inaccuracy was determined by calculating the percentage deviation of the measured 
concentration from the nominal values of each QC sample. 
 
 
2.7 Extraction recovery 
Extraction efficiency (%) was determined at two QC levels (LQC and HQC) by dividing 
the peak areas from extracted samples with those from spiked post-extracted blank cell 
extract samples at the same QC concentration. Recovery of the CPT was determined in 
the same way at a concentration of 1 µg/ml. 
 
2.8 Specificity for SN-38 and CPT 
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Specificity was evaluated by injecting blank mobile phase to conform that no peaks were 
co-eluting at the positions of SN-38, CPT. This was also repeated with drug free (blank) 
cell extract. 
 
2.9 Stability 
 
Stability of SN-38 and CPT were evaluated by repeated injection of standards after freeze 
thaw cycles over a 3 month period of time. 
 
2.10 Application of method 
 
This method was used to determine intracellular SN-38 concentrations in human cancer 
cell lines derived from colon cancer (HT29, HCT116 and SW620) in the presence and 
absence of fumitremorgin C (a known ABCG2 efflux inhibitor) and Ciclosporin A (P-gp 
efflux inhibitor). 
 
Cells were grown in appropriate media in 90 ml flasks, trypsinized and counted prior to 
the experiment. Samples of each cell line were then distributed to Falcon tubes at a 
concentration of 2 million cells /ml (3 ml in each falcon tube). Each sample was then 
treated with 0.1µM SN-38, with and without 10µM ciclosporin or 5 µM Fumitremorgin 
C. Incubated at 37
o
C for 2hrs to allow uptake/efflux to occur, after which, samples were 
spun at 600 g, 4
o
C, for 6min to pellet cells. After removal of supernatant the cells were 
washed once in ice cold hanks and transferred into 1.7ml Eppendorf tubes. Samples were 
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then re-spun at 600 g, 4
o
C, for 6 min to pellet cells. Cell extraction procedure was then 
carried out as previously described in section 2.3. 
 
3. Results 
 
3.1 Method development and optimisation 
Two different UPLC columns (PFP and HILIC) were investigated. SN-38 and CPT could 
not be chromatographically separated on the HILIC column (Kinetex HILIC, 2.1 × 
100mm) using 80% acetonitrile isocratic elution at a flow rate of 250µl. SN-38 peak full 
width at half maximum height (FWHM) was 0.1 minutes and retention time was 1.15 
minutes (data not shown). These results suggested that SN-38 was not retained enough on 
the HILIC column as the void time on this system was expected to be 0.96 minutes. 
However, the PFP column produced efficient retention and sharp peaks using a simple 
mobile phase gradient of water and ACN (Figure 2). Finally, the gradient was optimized 
to achieve high throughput analysis.  
 
3.2 Extraction recovery 
Extraction recoveries were reproducible and consistent across 6 independent experiments 
(total of 203 samples) with mean values of 98.5  13% for CPT. SN-38 recoveries at 
LQC and HQC (total of 24 samples) was 89  6% and 95  8%, respectively.  
 
3.3 Standard curves and linearity 
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The mean response factor across 6 experiments (standards were run in duplicate) was 
239.5  18.2 (Stdev). The average r2 was 0.9993  0.0016. (Table 1). The imprecision at 
the 0.1 ng/ml concentration was not acceptable (34.1%), so this calibrator point was 
removed from the standard curve used in quantifying intracellular SN-38.     
 
3.4 Imprecision and Inaccuracy 
Intra-day imprecision was less than 6.0% over 6 experiments. Highest imprecision was 
noted with LQC. The mean measured value for the LQC was 5.1 ± 0.3 with inaccuracy of 
1.2%. The mean measured concentration for HQC was 492.0 with inaccuracy of -1.6% 
(Table 2).  
 
Inter-day imprecision were less than 9.2% across 6 experiments. The mean measured 
value for the LQC was 5.1 ± 0.5 with inaccuracy of 1.9%. The mean measured 
concentration for HQC was 491.5 with inaccuracy of -1.7% (Table 2).  
 
3.5 Sensitivity 
As shown in Figure 2 (E) and Table 1, although SN-38 was detectable at a 
concentration of 0.1ng/ml, the imprecision at this concentration exceeded 10%. Therefore 
LOQ was identified as 0.3 ng/ml and LOD identified as 0.1 ng/ml. The impression at 
LOQ and LOD was 8 and 34%, respectively.  
 
3.6 Specificity 
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Extracted blank cell extract showed no peaks eluting at the retention times of SN-38 and 
CPT (1.75 and 1.89 minutes, respectively). Figure 3 (D & G) shows example 
chromatograms for blank cell extracts with no co-eluting compounds at the expected 
retention time of SN-38 and CPT, respectively. 
 
3.7 Freeze-thaw stability 
 
The results of the stability experiments are shown in Table 3. SN-38 stock solution was 
found to be stable at −40°C for 3 months with a concentration difference of less than 5% 
after 3 months of storage. The analytical method is therefore proved to be applicable for 
routine analysis over this period of time. 
 
3.8 Method Application 
Figure 3 shows that Ciclosporin A had little effect on the accumulation of SN-38 in the 
three colorectal cell lines with significant increase of 57% in HT29 cell line (p<0.05). 
These results suggest that ABCB1 has a minor role in SN-38 efflux. However, 
Fumitremorgin C (a specific ABCG2 inhibitor) resulted in a dramatic increase in SN-38 
intracellular concentrations in all colorectal cell lines with 4.3, 2.1 and 3.1 fold increase 
in HT29, HCT116 and SW620 cell lines, respectively. Combined administration of 
ciclosporin A and fumitremorgin C did not result in more SN-38 accumulation compared 
to fumitremorgin C alone treatment. These results suggest that SN-38 efflux in colorectal 
cell lines is mainly via ABCG2. 
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3.9 UPLC-MS/MS Vs HPLC-Flu Method Comparison 
This novel UPLC-MS/MS  method resulted in sharp peak shapes for both SN-38 and 
CPT. FWHM for SN-38 and CPT was >0.1 minute for UPLC-MS method compared to 
0.2 and 0.3 minutes, respectively for the HPLC-Flu method. The retention times obtained 
for the UPLC-MS method were 1.75 and 1.89 minutes for SN-38 and CPT, respectively 
compared to 3.7 and 4.6 minutes for the HPLC-Flu. This resulted in a shorter total run 
time for the UPLC-MS method (6 minutes compared to 7 minutes for HPLC-Flu). In 
addition, the UPLC-MS method had higher sensitivity with LOQ value of 0.3 ng/ml 
compared to 1 ng/ml for HPLC-Flu. The fluorescent detection of the HPLC-Flu method 
was saturated at a SN-38 concentration of 300 ng/ml, while the mass spectrometry 
detector of the UPLC-MS method detected SN-38 concentrations up to 10,000 ng/ml 
without saturation. Therefore, this novel UPLC-MS method covered a wider dynamic 
range (0.3-1000ng/ml compared to 1-200 ng/ml for HPLC-Flu). Imprecision and 
inaccuracy values were < 10% for both methods. The two methods were used to 
determine intracellular SN-38 concentrations in a panel of colorectal cancer cell lines. 
The results were then compared using Bland-Altman analysis in order to determine the 
degree of agreement between the two methods (Figure 3D). The average bias between 
the two methods was close to zero (0.16 ng/ml). In addition, the 95% limits of agreement 
were between +8.29 and -7.97 ng/ml.  
  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
15 
 
4. Conclusion 
The method described in this work is the first UPLC-MS method to be developed 
specifically for intracellular quantification of SN-38. The extraction method is simple and 
reproducible with high extraction yield. The method is highly sensitive, precise and 
accurate. A good separation was achieved with excellent peak resolution and minimal 
peak tailing without using any ion pairing agents. Moreover, the chromatography run 
time was shorter permitting high sample throughput. This method has been successfully 
applied to the measurement of intracellular SN-38 accumulation in a number of colorectal 
cell lines studying SN-38 efflux. In all the studied cell lines, SN-38 efflux was found to 
be mainly regulated by ABCG2 with minimal contribution of ABCB1. These results 
suggest that the newly developed UPLC-MS method is ideally suited for this type of 
analysis. 
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Figure Captions 
 
Figure 1. Chemical structure of irinotecan (A) and SN-38 (B) 
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Figure 2. Examples of mass spectral analysis of SN-38 (A) and CPT (B).  Typical 
standard curve for SN-38 is also shown (C) with quadratic curve fit. Example 
chromatograms produced using HT29 colon cancer cells, with blank cell extract with no 
SN-38 (D), lower limit of detection (LOD) at 0.1 ng/ml SN-38 (E) and SN-38 
accumulation at 33 ng/ml (F).  The internal standard CPT chromatograms are also shown 
in double blank cell extract (G) with no CPT and CPT concentration of 1 µg/ml added to 
the extraction solution (H).  
 
Figure 3. Intracellular accumulation of SN-38 before and after treatment with ABCB1 
(P-gp) inhibitor, ciclosporin (CA), ABCG2 (BRCP) inhibitor fumtremorgin C (FMC) and 
a combination of CA + FMC in three colorectal cell lines HT29, HCT116 and SW620 
corresponding to Figure A, B and C, respectively (NS = non-significant, * = significant 
with p<0.05 and *** = significant with p<0.001). Bland Altman plot showing the 
agreement in determining the SN-38 intracellular concentrations in the three colorectal 
cell lines between the UPLC-MS and HPLC-Flu is also shown (D)   
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 An UPLC-MS/MS method was developed for measuring intracellular concentrations 
SN-38 
 SN-38 was separated using a pentafluoryl phenyl UPLC column 
 Fast analysis and good peak shape obtained without the need for ion-pairing agents. 
 Method was used to investigate SN-38 efflux in colorectal cancer cell lines. 
 The method results were compared to a validated HPLC- fluorescent method.  
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Figure 3C) 
C) SW620
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Figure 3D) 
D) Bland Altman Plot
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Table 1, Measured Vs Theoretical concentrations of SN-38 standards along with Imprecision 
(CV) and Inaccuracy (percentage error). 
 
 
Theoretical 
Standards 
Mean of the 
Measured standards 
Imprecision (CV) Inaccuracy  
(Error %) 
0.1 0.11 34.1 6.2 
0.3 0.33 8.2 8.9 
1 0.98 8.9 -2.2 
3 3.06 7.3 1.9 
10 9.34 7.8 -6.6 
30 30.41 8.1 1.4 
100 95.58 7.4 -4.4 
300 306.21 7.0 2.1 
1000 965.74 3.0 -3.4 
 
 
 
 
  
Tables
 Table 2. Intra- and inter-day imprecision of SN-38. 
 
 
 Intraday (n=6) Interday (n=6) 
 LQC  MQC HQC LQC  MQC HQC 
Theoretical value 
(ng/ml)  
5.0 50.0 500.0 5.0 50.0 500.0 
Mean measured value 
(ng/ml) 
5.1 48.5 492.0 5.1 49.4 491.5 
SD 0.3 0.9 23.5 0.5 1.5 35.1 
Imprecision (CV) 6.0 1.9 4.7 9.2 2.9 7.1 
Inaccuracy (Error %) 1.2 3.0 -1.6 1.9 -1.2 -1.7 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 3. SN-38 stability experiments carried out on 3 cycles over a period of 90 days. 
 
  Std 30 Std 3 
Cycle 1 32.715  3.097  
Cycle 2 30.93 3.16 
Cycle 3 32.40 3.14 
      
Mean 32.01 3.13 
Std 0.95 0.03 
Imprecision (CV) 2.98 0.95 
Inaccuracy (Error %) -2.01 -0.13 
 
